Filing Overview
Registrant: Flora Growth Corp., not Zerostack Corp. as indicated in the request metadata. The Form 8-K reports events dated December 15, 2023 and was signed December 21, 2023. The filing concerns executive employment and compensation arrangements under Item 5.02.
Executive Compensation and Key Terms
| Executive | Role | Base salary | Equity award |
|---|---|---|---|
| Clifford Starke | Chief Executive Officer | $420,000, retroactive to his appointment date | Stock appreciation rights representing 12% of outstanding shares at grant, in 12 tranches of 1% each |
| Dany Vaiman | Chief Financial Officer | $275,000, retroactive to his appointment date | Stock appreciation rights representing 4% of outstanding shares at grant, in 8 tranches of 0.5% each |
Both agreements have indefinite terms unless terminated under their provisions. Salaries may be increased by the Board. The executives may participate in equity, benefit, incentive, and other plans available to senior executives; the CFO is also entitled to paid time off and holiday pay under company policy.
Equity Award Conditions
- The SAR exercise price is the closing share price on the grant date.
- For Mr. Starke, tranches vest as the share price increases from 50% through 600% above the grant-date closing price, in successive 50% increments.
- For Mr. Vaiman, tranches vest as the share price increases from 50% through 400% above the grant-date closing price, in successive 50% increments.
- The SARs expire 10 years after grant and generally have a one-year post-termination exercise period.
- All SARs remain unexercisable and subject to forfeiture unless approved by shareholders at the Company’s annual meeting.
Severance and Change-in-Control Provisions
If either executive is terminated without Cause or resigns for Good Reason, subject to signing a separation and release agreement, the executive is eligible for severance equal to 1.5 times the applicable base salary. Half is payable in a lump sum shortly after the release agreement becomes effective, with the remainder payable in 12 equal monthly installments.
The same severance eligibility applies if the termination without Cause or resignation for Good Reason occurs within three months before or after a Change in Control, as defined in the applicable agreement.
Financial Metrics and Outlook
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or operating forecasts. It also does not quantify the grant-date share price or the number of shares represented by the SAR awards.
Material Changes and Unusual Items
The material reported changes are the formalization or continuation of the CEO and CFO roles through new agreements and the associated contingent SAR awards and severance arrangements. The awards require shareholder approval and could result in future dilution if approved, vested, and exercised; the filing does not provide a dollar valuation or precise share count.
Investor Verification Points
- Confirm the correct issuer: the filing identifies Flora Growth Corp. and ticker FLGC, whereas the request identifies Zerostack Corp.
- Review the full Starke and Vaiman agreements for the definitions of Cause, Good Reason, and Change in Control.
- Verify whether shareholders approve the SAR grants at the annual meeting.
- Determine the grant-date closing share price, accounting fair value, and potential dilution represented by the SARs.
- Assess the financial statement impact of the compensation arrangements and any resulting severance obligations.